PL3960195T3 - Engrailed do zastosowania w leczeniu stwardnienia zanikowego bocznego - Google Patents

Engrailed do zastosowania w leczeniu stwardnienia zanikowego bocznego

Info

Publication number
PL3960195T3
PL3960195T3 PL21189549.5T PL21189549T PL3960195T3 PL 3960195 T3 PL3960195 T3 PL 3960195T3 PL 21189549 T PL21189549 T PL 21189549T PL 3960195 T3 PL3960195 T3 PL 3960195T3
Authority
PL
Poland
Prior art keywords
engrailed
treatment
lateral sclerosis
amyotrophic lateral
amyotrophic
Prior art date
Application number
PL21189549.5T
Other languages
English (en)
Inventor
Alain Prochiantz
Original Assignee
Centre National De La Recherche Scientifique
Institut National De La Sante Et De La Recherche Medicale - Inserm
College De France
Sorbonne Universite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherche Scientifique, Institut National De La Sante Et De La Recherche Medicale - Inserm, College De France, Sorbonne Universite filed Critical Centre National De La Recherche Scientifique
Publication of PL3960195T3 publication Critical patent/PL3960195T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL21189549.5T 2015-09-23 2016-09-23 Engrailed do zastosowania w leczeniu stwardnienia zanikowego bocznego PL3960195T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15306482 2015-09-23

Publications (1)

Publication Number Publication Date
PL3960195T3 true PL3960195T3 (pl) 2025-06-09

Family

ID=54207439

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21189549.5T PL3960195T3 (pl) 2015-09-23 2016-09-23 Engrailed do zastosowania w leczeniu stwardnienia zanikowego bocznego
PL16777596T PL3352777T3 (pl) 2015-09-23 2016-09-23 Engrailed do stosowania w leczeniu uszkodzenia dna u pacjentów cierpiących na chorobę parkinsona

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16777596T PL3352777T3 (pl) 2015-09-23 2016-09-23 Engrailed do stosowania w leczeniu uszkodzenia dna u pacjentów cierpiących na chorobę parkinsona

Country Status (8)

Country Link
US (2) US20190247461A1 (pl)
EP (2) EP3960195B1 (pl)
JP (1) JP6860575B2 (pl)
CN (1) CN108289929A (pl)
CA (1) CA2999209A1 (pl)
ES (2) ES3010130T3 (pl)
PL (2) PL3960195T3 (pl)
WO (1) WO2017071889A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024207403A1 (en) 2023-01-13 2025-07-24 Brainever Stabilized engrailed protein aqueous compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662698A1 (fr) 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
FR2855178B1 (fr) * 2003-05-20 2005-08-05 Centre Nat Rech Scient Peptides modulateurs de l'activite du facteur de transcription engrailed
FR2897780B1 (fr) 2006-02-28 2008-05-23 Centre Nat Rech Scient Utilisation de la proteine a homeodomaine engrailed comme anxiolytique
GB0625321D0 (en) * 2006-12-19 2007-01-24 Univ Surrey Cancer biomarker
FR2926023B1 (fr) 2008-01-09 2010-02-26 Centre Nat Rech Scient Utilisation d'une homoproteine de la famille bicoid pour le traitement du glaucome.
US20120177672A1 (en) * 2009-07-13 2012-07-12 The University Of Surrey Therapeutic peptides, polypeptides and nucleic acid sequences
WO2013128239A1 (en) * 2012-02-29 2013-09-06 Centre National De La Recherche Scientifique Use of engrailed for increasing dopamine synthesis by dopaminergic neurons

Also Published As

Publication number Publication date
CA2999209A1 (en) 2017-05-04
ES3010130T3 (en) 2025-04-01
EP3352777A1 (en) 2018-08-01
PL3352777T3 (pl) 2022-02-07
EP3352777B1 (en) 2021-09-15
US20190247461A1 (en) 2019-08-15
WO2017071889A1 (en) 2017-05-04
EP3960195B1 (en) 2025-01-08
JP6860575B2 (ja) 2021-04-14
JP2018536697A (ja) 2018-12-13
US20210379144A1 (en) 2021-12-09
EP3960195A1 (en) 2022-03-02
ES2895154T3 (es) 2022-02-17
CN108289929A (zh) 2018-07-17

Similar Documents

Publication Publication Date Title
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
MA45192A (fr) Traitement d'association
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
PL3265053T3 (pl) Sposoby leczenia skóry
DK3474802T3 (da) Medicinsk forbinding
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
EP3409744A4 (en) SURFACE TREATMENT AGENT
DK3778595T3 (da) Pancreatitisbehandling
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
PL3381451T3 (pl) Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
EP3380200A4 (en) COMPOSITIONS FOR TREATING THE HAIR
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
PL3186244T3 (pl) Analogi dioksolanowe urydyny w leczeniu raka
EP3431566A4 (en) SURFACE TREATMENT AGENT
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
EP3380063A4 (en) COMPOSITIONS FOR TREATING THE HAIR
IL256206A (en) Mct4 inhibitors for treating disease
DK3373874T3 (da) Medicinsk forbinding
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
HUE053927T2 (hu) Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
EP3309165A4 (en) SURFACE TREATMENT AGENT